Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (November 2006)
21 slides from Medical Developments International's investor presentation, Nov 27, 2006
Slide 1: Broker Presentation November 2006
Medical Developments International Medical Developments International Limited Pre Hospital Analgesia (and other applications) Broker Presentation November 2006
Slide 2: An Australian pharmaceutical company focused on
An Australian pharmaceutical company focused on: . Medical - Developing our leading pre hospital pain re for a range of applications in humans and a world markets. — . - Developing and exporting our asthma and oxygen — devices and equipment. — Developments international
Slide 3: Pharmaceutical and Medical and Veterinary Equipment
« Pharmaceutical .- _--. TGA, Medsafe (NZ) and GCC Registrations “+ Plant is GMP. certified ; - Single product (PenthroxTM — inhaled analgesic) ° --Only manufacturer in the world -°... ~.- Currently used i in ambulance, military, hospitals, sport, dentistr and * Medical and Veterinary Equipment “= K
Slide 4: Asthma, Oxygen Equipment and Veterinary
Asthma Maintenance of sole supplier in NZ Launch in Asia and Europe ‘Oxygen Equipment > Launch for Dentists and G.P's Veterinary : Eastern European push Medical Developments international
Slide 5: Multi-level Strategy
lulti-level: Strateg Local sales and new therapeutic areas to deliver Developments international
Slide 6: Penthrox Methoxyflurane Growth Strategy
Penthrox Double digit growth is expected in established markets ‘during FYO7. Methoxyflurane Growth Strategy New. — Current Medical Interventional radiology Phlebology Aesthetic and Plastic surgery Podiatry Dentistry Hospitals (burns/accident and emergency) Military Ambulance Sports and rescue medic
Slide 7: Outlook: Significant growth from new markets - Dentistry
utlook: ‘Significant gro yth from new Dentistry «Product launched in ai 2006 and distributed by Henry. Schein, one of the world’s leading distributors of dental products «The launch has been backed with ~*a national lecture circuit - advertising in industry publications; and. *some. popular media co
Slide 8: Growth Strategy - Penthrox (Domestic)
Growth Strategy ~ Penthrox (Domestic) Penthrox™ addresses the major issues in dentistry: pain and anxiety management “Examples of Use « Administration of local anaesthetic «Initial examination of patients.in pain « Removal of temporary ~crown/bridges «Hand scaling and root planning + Ultrasonic scal
Slide 9: Outlook: Significant growth from new markets - Dentistry
Outlook: Significant growth | Dentistry “Penthrox arrived Monday lunch in the post. At 4pm had a 13 year old female for 14 24 ortho exos. She was crying and very anxious having spent all holidays getting psyched for the visit. Amazing what a difference Penthrox made from new markets “Just finished t
Slide 10: Outlook: Hospitals and Burns
Outlook: Significant growth from new markets eee ~~ Hospitals - *Significant sales are expected in FYO7- Distributor appointed «Formulary submissions -New trial data is being generated in pediatrics: —with upper. limb fractures (Westmead Hospital) —transported to the Emergency. Department (RCH) Emer
Slide 11: Plastic and Cosmetic Surgery
markets. look: Significant growth from new Plastic and Cosmetic Surgery ‘Distributor appointed : *Current use. significant “Opinion Leader Support *Penthrox is ideal for: ‘—Pre- treatment analgesia «During non-invasive procedures, such as: —Injections : -—Mesotherapy Dermal fillers -—Dermabrasion an
Slide 12: Interventional Radiology, Oncology and Palliative Care
ignificant gro ‘th from ne\ markets. Interventional Radiology, Oncology and Palliative Care . «Protocol under ethical review, Peter Mac ‘Existing sales in imaging *Bone marrow biopsy *Cliniclans comments included; “Excellent in relaxing the patient and in relieving pain quickly” *"Penthrox helped us
Slide 13: Outlook: Sport
Outlook: Significant growth from new markets | Sport Commonwealth Games *AFL. Clubs ° «Australian and New Zealand Ski fields *Super 12 Rugby «Australian and English World Cup Soccer Teams *Three UK Premier League Clubs, under “Named Patient Program’ -.*Extreme sports: Survivor Program Medical Develo
Slide 14: Outlook: Veterinary
Outlook: Signifi cant growth from new markets Veterinary Opportunity Current registration -USA > Registered Manufacturing site — Australia Previously Registered — Austria, Australia, Canada, France, Germany, : Switzerland, Trinidad, UK Registration Process. Agreement signed with Schering- Plough Ani
Slide 15: Penthrox: multiple therapeutic areas
enthrox Multiple therapeutic areas allow numerous entry strategies in new countries eT ey iy Medical Developments : 15 international
Slide 16: Methoxyflurane Growth Strategy
New _ Current Medical Methoxyflurane Growth Strategy _ Interventional radiology GCC (Bahrain, Oman, Qatar, UAE, Phlebology Saudi Arabia, Kuwait) Aesthetic and plastic surgery : Podiatry Dentistry ~ Hospitals (burns/accident and emergency) Paki Ru Singapore, Military Ambulance Sports and rescue medic
Slide 17: Penthrox - Gulf, Asia, Eastern Europe
Penthrox — Gulf GCC Committee Approval Individual Country Registration Existing Sales Pakistan - Revised dossier under review Turkey — Dossier submitted, initial questions Lebanon and Egypt in planning Sth. East Asia (Sing, Thai, HK, Phil, Viet, Mal, indo) Initial submission complete First Questions
Slide 18: Penthrox - South and Central America
| Penthrox — Sth. and Central Chile -Initial submission complete. “Questions round complete Final questions responded to Process begun in Peru, Bolivia, -- Paraguay, and Ecuador . Guatemala : Final questions responded to Mexico Regulatory agent appointed Nov. Argentina - : me : Regulatory agent appo
Slide 19: Penthrox - Europe and North America
Penthrox — Europe and North America Europe . “Dossier under. review by-Reg consultant Reg strategy advice end November US . FDA Advice. Received Preclinical Plan under internal review Clinical Study submitted to Peter Mac ethics Expected start Feb 07 Canada ; In discussions re “Named Patient Program
Slide 20: Financial Profile 2006
Financial Profile 2006 Business Unit Sales. _Gross.Profit $’000 $000 6,560 4,325 - EBITDA - . $4,554k ‘EBIT $1,310k «Cash Flow from operations : eee $4, 152k «Investment in Marketing and Registrations $44 77k $192k deferred) Medical Developments international 20
Slide 21: Summary: Forecast substantial increase in profit FY2007/FY2008
summary: Forecast substantial increase in_ profit FY2007/FY20 | | + Double.digit growth in the core business driven by: -=Dentistry and hospital sales in Australia/New. Zealand « Part year Middle East sales Part year sales in aesthetic. surgery, podiatry and imaging «Costs are expected to.decline as
Medical Developments International — Investor Presentation (November 2006) on 6ix